Brokerage firm JM Financial has initiated 'Buy' coverage on Acutaas Chemicals, forecasting a 28% earnings growth rate through 2030. The optimistic outlook is driven by expanding contract manufacturing volumes and entry into semiconductor chemicals. The stock is currently trading around ₹3,400 following recent market gains.
Acutaas Chemicals is in focus after brokerage firm JM Financial initiated coverage on the company with a 'Buy' rating and a price target of ₹3,800. The stock has shown movement, trading in the range of ₹3,380 to ₹3,412 on September 11, 2026, following a 7% gain in the previous trading session.
Growth Drivers and Strategic Focus
The brokerage’s positive stance is supported by the company’s pivot toward high-value growth segments. The primary driver is the Contract Development and Manufacturing Organization (CDMO) business, where analysts project a 28% compound annual growth rate through 2030. This is largely tied to the anticipated tripling of Daro-volumes to 160 tonnes, supported by the clinical success of the Nubeqa patient base. Beyond pharmaceuticals, the company is aggressively scaling its presence in specialty chemicals. Revenue from this division is projected to reach ₹730 crore by 2030, up from ₹160 crore in fiscal year 2026. This expansion is focused on electrolyte additives and chemicals designed for the semiconductor and electronics industries, which typically command better profit margins.
Financial Performance and Operational Support
The company’s recent performance reflects its growth strategy. In the first quarter of fiscal year 2027, the company reported revenue from operations of ₹329.67 crore, marking a 59.1% increase compared to the same period last year. Profitability remains healthy, with EBITDA margins expanding to 34.3%. Operational efficiency has been boosted by government support, including subsidies for its Jhagadia electrolyte facility under the Electronics Components Manufacturing Scheme, which involves an investment of approximately ₹119.12 crore. Additionally, the company is strengthening its intellectual property portfolio, recently securing a process patent for 2,4-dimethylthiophenol, bringing its total to 11 patents.
Risks and Monitorables
While the growth outlook is positive, investors should be aware of several business risks that could impact future performance. The specialty chemicals sector faces inherent challenges, including potential volatility in raw material prices, which can put pressure on profit margins. Additionally, the company faces execution risks related to the large-scale commercialization of new electrolyte additives and the ramp-up of semiconductor chemical production. Being an export-oriented player, Acutaas Chemicals is also exposed to fluctuations in foreign exchange rates and intensified global competition. The company’s ability to maintain its margin profile amidst these sector-wide pressures and manage project timelines will be key for shareholders to track in the coming quarters.